Epilepsy: annual review

Indicator

The percentage of adults receiving drug treatment for epilepsy who had a structured review in the preceding 12 months.

Resource impact

The prevalence of adults receiving drug treatment for epilepsy is around 0.8% (Quality and Outcomes Framework, 2020–21). This is equivalent to around 63 adults per 10,000 population (Office for National Statistics, 2020).

Robust data for the number of these people who had a structured review in the preceding 12 months is not available. It is estimated that for every 10% increase in the number of people in this population who have a structured review, an additional 6 people per GP practice will have a structured review (see table 1).

Table 1 Estimated impact on activity for a theoretical 1%, 5% and 10% increase in the proportion of adults having a structured review (based on 10,000 registered patients in a GP practice)

Current number of structured reviews	Increased number of structured reviews with a 1% increase	Increased number of structured reviews with a 5% increase	Increased number of structured reviews with a 10% increase
Varies locally	1	3	6

Due to the small numbers involved, the impact on general practice is anticipated to be minimal and the resource impact associated with any increase will not be significant.